Inmunología Tumoral

Publicaciones

  • 01/02/2018

    Cancer Research

    Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis

    Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino MF, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani V, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

  • 28/12/2017

    BMC Cancer

    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer

    Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, Allemand DH, Figurelli S, Deza EG, Ares S, Gercovich FG, Cortese E, Amasino M, Guzmán P, Roa JC, Elizalde PV, Schillaci R.

  • Cells

    16/08/2017

    Genes (Basel)

    Distribution of FMR1 and FMR2 Repeats in Argentinean Patients with Primary Ovarian Insufficiency

    Espeche LD, Chiauzzi V, Ferder I, Arrar M, Solari AP, Bruque CD, Delea M, Belli S, Fernández CS, Buzzalino ND, Charreau EH, Dain LB.

  • Immunology and Cell Biology

    03/04/2017

    Immunology and Cell Biology

    Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway

    Velásquez LN, Milillo MA, Delpino MV, Trotta A, Mercogliano MF, Pozner RG, Schillaci R, Elizalde PV, Giambartolomei GH, Barrionuevo P.

  • 01/02/2017

    Clinical Cancer Research

    TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer (Seleccionado como Cover Image y Highlight)

    Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R.